PPAG RSS Feed

22nd Annual PPAG Meeting and 2013 Pediatric Pharmacy Conference on 1-May-13 8:30 AM

Wed, 01 May 2013 13:30:00 GMT

22nd Annual PPAG Meeting and 2013 Pediatric Pharmacy Conference
Start Date: 1-May-13 8:30 AM
End Time: 5-May-13 5:30 PM
Location: Indianapolis Marriott Downtown, Indianapolis, IN 46225
Event Details:

The 22nd PPAG Annual Meeting and 2013 Pediatric Pharmacy Conference is designed for practitioners and administrators involved in drug therapy decisions for children. The Conference is designed by pediatric pharmacists who understand the unique needs of the pediatric patient. This conference will provide important educational benefits for participants who want to improve their positioning in the health care enviornment. It will also provide a new understanding of current medical and clinical trends in pediatric health care. The overall conference goals are as follows: Provide and review current information and developments pertaining to pediatric medication use in neonatal and pediatric critical care. Review new technologies that can reduce the risk of errors in the pediatric population. Discuss new drugs on the market and their application to pediatric patient care. Provide a forum for the exchange of information and ideas among pediatric practitioners. The 22nd Annual PPAG Conference features two educational blocks. The Pediatric Critical Care Block will is offered May 1-3, 2013 and the Neonatal Critical Care Block will be held from May 3-5, 2013. Participants can participate in both blocks.
Conference Agenda Information TBA Call For Abstracts TBA	Registration Information and Policy TBA
Hotel Information-- Affordable Rates! The Indianapolis Marriott Downtown has been chosen as the official hotel of the 22nd PPAG Annual Meeting and 2013 Pediatric Pharmacy Conference. PPAG has secured a room-rate of $165.00 per night. Individual attendees are responsible for making their own hotel reservations. You can make reservations by calling 1-800-266-9432. You can also make your reservations online. You must indicate that you are attending the "PPAG Pediatric" event. Reservations must be made on or before Sunday, March 31, 2013.	About Indianapolis, IN For more information about Indianapolis, pleae visit the Visit Indianapolis website: http://visitindy.com/
The Pediatric Pharmacy Advocacy Group is an approved by the Accrediting Council of Pharmacy Education as a provider of pharmacy education. The 22st Annual PPAG Meeting and Pediatric Pharmacy Conference offers up to 28 continuing educational contact hours. To receive credit participants must attend the session and fill out the online verification of attendance and conference evaluation form. Certificates will be send 3-4 weeks after the completion of the conference. Participants will not receive credit if there is a balance due on their account. PPAG will disclose any financial support received from the pharmaceutical industry during the conference. The PPAG Education Committee makes substantial effort to present conference materials in an unbiased manner. PPAG educational programming is 100% supported by registration and member fees. Any grievance should be sent directly to the PPAG Executive Director.

Indianapolis Marriott Downtown

350 West Maryland Street

Indianapolis, IN US 46225

Highlighting Member Publication: Spencer Durham

Kim Benner - noemail@ppag.org — Tue, 01 May 2012 12:00:00 GMT

The PPAG Research Committee is shining the spotlight on member research and publications. Spencer H. Durham, Pharm.D., BCPS, is a clinical pharmacist specializing in the areas of pediatrics and infectious diseases at Sacred Heart Hospital in Pensacola, FL. He is a 2007 graduate of the Auburn University Harrison School of Pharmacy and a 2008 graduate of the PGY-1 pharmacy residency program at Children’s Health System in Birmingham, AL.

During Dr. Durham’s residency training, a sentinel event occurred with a young patient after receiving one dose of meperidine. As a member of the Formulary Subcommittee of the Pharmacy and Therapeutics Committee, he was asked to evaluate the use of meperidine throughout the health system with his residency mentor, Dr. Kim Benner. In order to prepare for this project, he wanted to investigate what was in the medical literature about the use and/or restriction of meperidine in the pediatric population. Although the potential serious toxicities of meperidine have been extensively documented in adults, as has been the removal or restriction of meperidine in adult hospitals, the literature was remarkably scarce in pediatric patients, consisting of only a few case reports of toxicities and no reports of removal or restriction in children’s hospitals. After carefully examining the overall use of meperidine at their institution, a restriction policy was put into place that limited the use of meperidine. The restriction policy was an overall success, resulting in a dramatic decrease in the use of this potentially highly toxic agent. Dr. Durham hopes that his experience with limiting the use of meperidine will help guide other healthcare professionals in implementing similar policies to minimize the use of this agent in children.

This research was reported in Benner KW, Durham SD. Meperidine Restriction in a Pediatric Hospital. J Pediatr Pharmacol Ther 2011;16(3): 185-90.

1-May-12 7:00 AM

FDA alert regarding accidental exposure to fentaNYL patches

Jeff Low - noemail@ppag.org — Thu, 26 Apr 2012 19:00:00 GMT

On April 18, 2012, the U.S. Food and Drug Administration (FDA) alerted healthcare providers and consumers about the importance of proper storage, application, and disposal of transdermal fentaNYL (fentaNYL patch) to prevent dangerous, accidental pediatric exposure. FDA noted 26 cases of accidental pediatric exposure during the past 15 years, including 10 that resulted in death and 12 that resulted in hospitalization. Sixteen events involved children 2 years old or younger. Incidents have occurred in the home but can also originate within a healthcare institution, where children may accompany adults who are visiting patients.

http://www.ismp.org/nan/files/nan-20120425.pdf

26-Apr-12 2:00 PM

Decision '12: Board Election Results

Matthew Helms - noemail@ppag.org — Thu, 05 Apr 2012 16:00:00 GMT

PPAG is pleased to announce the new members of the Board of Directors and Executive Committee. These individuals will be joining incoming President Amy Potts, PharmD, Immediate-Past President David Knoppert, MScPharm, and Directors-At-Large Timothy Todd, PharmD, Jared Cash, PharmD, Michael Chicella, PharmD

PPAG is governed by an eleven (11) member Board of Directors, consisting of five (5) Executive Committee members and six (6) Director-At-Large.

President-Elect
William (Bill) Maish, PharmD

Bill Maish, PharmD is an Acute Pediatrics Clinical Pharmacist Specialist at the Arnold Palmer Medical Center in Orlando, Florida.

Dr. Maish has been an active member of PPAG for more than 18 years and has been active on the Membership Services Committee during that time. He has served on the Board of Directors for the past 3 years. He worked on projects such as writing newsletter articles and editing PPAG newsletters. After serving as the Member Services Committee Chair, Bill became the Vice-President for Member Services in 2007, where he worked on projects such as editing PPAG newsletters, soliciting member feedback and implementing improvements on the PPAG website, conducting membership surveys, and participating in Membership campaigns. Bill has provided lectures and workshops at PPAG Annual Meetings. He also served as an Abstract Reviewer, reviewer for JPPT article, and assisted in editing an ambulatory care learning module. He has committed to coauthor the Asthma Ambulatory Care Learning module.

Treasurer
Jeffrey Low, PharmD

Jeff Low is the Clinical Pharmacist Specialist-Pediatrics at the Children's Hospital at Dartmouth.

Dr. Low has served on the Board of Directors since 2006, and served as Chair from 2008-2009. Dr. Low has participated on the research & member services committees. From 2003-2005, he served as the Vice-President for Member Services, where he has worked on projects such as the PPAG website upgrades, membership survey, PPAG newsletter, and launching online CE.

This will be Dr. Low's second term as Treasurer of PPAG. In this role, he oversees the internal audit, budget development, and fiscal evaluation of programs.

Secretary
Kay Kyllonen, PharmD, FPPAG

Dr. Kyllonen is a Clinical Specialist in the Neonatal Intensive Care Unit at the Cleveland Clinic in Cleveland, OH.

Dr. Kyllonen served on the PPAG Board of Directors this past year. She has served on the Education Committee for serveral years, and was the chairperson of the 2009 PPAG Annual Conference in Cleveland, OH. She received FPPAG recognition in 2009. She has presented during PPAG Annual Conferences.

Director-At-Large (2012-2015)
Tracy Hagemann, PharmD, FCCP, FPPAG

Tracy M. Hagemann, Pharm.D., FCCP, is an Associate Professor at the University of Oklahoma College of Pharmacy and serves as director of the PGY2 Pediatric Pharmacy at OU. She also is Adjunct Associate Professor for OU College of Medicine, Department of Pediatrics. She currently maintains an active clinical practice in pediatrics and pediatric hematology/oncology at the Children’s Hospital at OU Medical Center. Dr. Hagemann received her Pharm.D. degree from the University of Missouri-Kansas City and completed her pharmacy practice residency at the Regional Medical Center at Memphis, Tennessee. She completed her pediatric residency at the University of Oklahoma where she has been a faculty member since 1996.

Tracy has been an active member of PPAG since 1996. She has been an invited speaker and has presented her research at many PPAG meetings. She has served as PPAG Clinical Focus Group Leader – Hematology/Oncology (1998-2003), as Chair of the 2005 PPAG Spring Specialty Meeting on Hematology/Oncology, and has been a member of the Education committee since 2008. She has been an author for several textbook chapters and publications, including Pharmacotherapy Essentials, Pediatric Pharmacotherapy and PSAP VII. She serves on the editorial board for The Journal of Pediatric Pharmacology and Therapeutics.

Director-At-Large (2012-2015)
David Hoff, PharmD, FCCP

David Hoff, PharmD, FCCP is a pharmacy Clinical Leader and member of the Professional Staff at Children’s Hospitals and Clinics of Minnesota. He also serves as the manager of the organization’s Medication Safety Value Stream. He holds clinical faculty appointments at the University of Minnesota and Drake University and is an intermittent pharmacist on the Minnesota-1 Disaster Medical Assistance Team, National Disaster Medical System. He is a graduate of the University of Minnesota. He has been a pediatric pharmacy practitioner, leader, and preceptor for over 20 years. He is a member of PPAG and the American College of Clinical Pharmacy (ACCP). He has served as a reviewer for articles submitted to the Journal of Pediatric Pharmacology and Therapeutics since 2003 and presented three lectures and one poster at national PPAG meetings.

Dr. Hoff is a fellow of ACCP. He serves on the Community Advisory Panel of the ACCP Practice Based Research Network, is a past Chair of the ACCP Pediatrics Practice and Research Network and is a past President of the Minnesota College of Clinical Pharmacy. He has served on the Children’s of Minnesota Board Quality Committee and two other nonprofit ministry boards. He has served as a consultant in pediatric pharmacotherapy to the pharmaceutical industry, Children’s HeartLink and to the Kingdom of Saudi Arabia. In 2008, he was the recipient of the Health Care Hero Award by Twin Cities Business magazine. He has published book chapters, original research and abstracts and presented lectures locally, nationally, and internationally on a number of pediatric medication topics. He is also a reviewer for three national pediatric pharmacotherapy journals. His main areas of professional interest are pediatric and neonatal critical care and medication safety.

Director-At-Large (2012-2013)
Lisa Lubsch, PharmD

Lisa Lubsch, PharmD has been appointed by the Board of Directors to complete the transition to an 11 member Board.

Lisa Lubsch, PharmD has most recently served as Chair of the PPAG Education Committee. She served as Chair of the 19th Annual PPAG Annual Meeting and Pediatric Pharmacy Conference in St. Charles, Missouri.

Dr. Lubsch is Clinical Assistant Professor in the Pharmacy Practice Department at the Southern Illinois University Edwardsville School of Pharmacy and Clinical Pharmacy Specialist at Cardinal Glennon Children’s Medical Center. Dr. Lubsch received the B.S. and Doctorate of Pharmacy from the St. Louis College of Pharmacy and completed a pediatric specialty residency at the Texas Tech University Health Sciences Center School of Pharmacy.

She currently provides pharmacist-delivered patient care to children on the pulmonary, cardiology, and a general medicine service. Her current areas of interests are pediatric asthma, cystic fibrosis, and addiction medicine.

5-Apr-12 11:00 AM

Fellows in the Pediatric Pharmacy Advocacy Group (FPPAG) Inductees Announced

Matthew Helms - noemail@ppag.org — Thu, 05 Apr 2012 15:00:00 GMT

PPAG is pleased to announce the 2012 FPPAG Inductees. Fellows in the Pediatric Pharmacy Advocacy Group (FPPAG) are recognized for distinguished professional accomplishments in pharmacy practice, research, and education as well as service to the pediatric pharmacy profession, especially PPAG.

The new Fellows will be introduced during the 21st PPAG Annual Conference on April 20, 2012 on Houston, Texas.

Tracy M. Hagemann, PharmD, FCCP, FPPAG

Tracy M. Hagemann, PharmD, is an Associate Professor at the University of Oklahoma College of Pharmacy and serves as director of the PGY2 Pediatric Pharmacy at OU. She also is Adjunct Associate Professor for OU College of Medicine, Department of Pediatrics. She currently maintains an active clinical practice in pediatrics and pediatric hematology/oncology at the Children’s Hospital at OU Medical Center. Dr. Hagemann received her Pharm.D. degree from the University of Missouri-Kansas City and completed her pharmacy practice residency at the Regional Medical Center at Memphis, Tennessee. She completed her pediatric residency at the University of Oklahoma where she has been a faculty member since 1996.

Tracy has been an active member of PPAG since 1996. She has been an invited speaker and has presented her research at many PPAG meetings. She has served as PPAG Clinical Focus Group Leader – Hematology/Oncology (1998-2003), as Chair of the 2005 PPAG Spring Specialty Meeting on Hematology/Oncology, and has been a member of the Education committee since 2008.

Dr. Hagemann has made significant contributions to pediatric pharmacy over the last 17 years through service, scholarship/research, and teaching. She has maintained an active practice site as a clinical pharmacist in the area of pediatric hematology and oncology. Dr. Hagemann has been instrumental in supportive care issues including pain management and nutrition. Through these efforts, she was one of the founding members of our pediatric pain management and palliative care committee at The Children’s Hospital at OU Medical Center.

She has also been instrumental in public health initiatives for children. Dr. Hagemann helped to establish dosing recommendations for children in the event of bioterrorism emergencies. These recommendations were recognized by the Oklahoma State Department of Health and the Centers for Disease Control. Dr. Hagemann has also served on several state initiatives within the Oklahoma State Department of Health to promote immunizations in children. She currently serves on the Immunization STAT Committee and Oklahoma Immunization Action Committee and has provided input to these agencies on the role that a pharmacist can have in immunizing children.

Dr. Hagemann has been extensively involved in professional organizations championing for pediatric pharmacotherapy. She has severed on numerous committees for the American Association of Colleges of Pharmacy, American College of Clinical Pharmacy (ACCP), and the Pediatric Pharmacy Advocacy Group. Dr. Hagemann served as the ACCP PRN Chair from 2008-2009.

Dr. Hagemann has also been active in scholarship/research and teaching in the area of pediatric pharmacotherapy. She has authored over 30 peer-reviewed publications, 6 book chapters, and 45 abstracts. In addition, she currently serves as an editor for Pediatric Injectable Drugs: The Teddy Bear Book.

Dr. Hagemann has also been actively involved in training future pharmacists in the area of pediatric pharmacy. She currently serves as the PGY2 Pediatric Pharmacy Residency Director and Director of the Pediatric Pharmacotherapy Fellowship. Dr. Hagemann has trained 6 PGY2 residents and 1 fellow. She has also served as a Thesis Chair for 2 Pharm.D./M.S. Master students whose thesis projects focused on pediatric hematology/oncology. Dr. Hagemann has also been instrumental in developing 2 novel pediatric electives for Pharm.D. students. She has also been instrumental in establishing immunization training programs across the state of Oklahoma. As a result of her efforts, she has trained over 500 pharmacists and/or pharmacy students.

Kristin Klein, PharmD, FPPAG

Kristin Klein, PharmD is the pediatric infectious diseases clinical pharmacist at the University of Michigan Health System (UMHS) and a Clinical Associate Professor at the University of Michigan (UM) College of Pharmacy. Dr. Klein received her B.S. in Pharmacy from Southwestern Oklahoma State University and her Doctor of Pharmacy degree from the University of Oklahoma. She then completed a specialty residency in Pediatric Pharmacotherapy at the University of the Sciences in Philadelphia. Following her residency, Dr. Klein joined the faculty of the University of Missouri-Kansas City, where she practiced in a neonatal intensive care unit until she joined the faculty at the University of Michigan. Dr. Klein is especially interested in training future practitioners. She spent four years serving on the UMHS pharmacy residency advisory committee, including two years as the committee’s co-chair. Dr. Klein is currently the co-chair of the admissions committee, the co-advisor of the APhA-ASP chapter and the faculty mentor for a new pediatric pharmacy student interest group at UM.

Her service to PPAG includes: serving on the Advocacy committee since 2002, co-authoring several position statements on behalf of the Advocacy committee, co-authoring several parental handouts for the KidsMeds website, co-chairing the Advocacy committee since 2009 and serving as an invited reviewer for the Journal of Pediatric Pharmacology and Therapeutics (JPPT).

Dr. Klein is dedicated to safe and effective medication use in pediatric patients. Dr. Klein has a number of publications in peer-reviewed journals, and has established a consistent track-record in this regard.

Dr. Klein has received grant funding to study the pharmacokinetics of oseltamivir in pediatric patients, ethanol locks in the management and prevention of catheter-related infections, transplacental passage of vancomycin following single dose administration prior to cesarean section, and IVIG for the prevention of respiratory exacerbations in ventilator-dependent children.

Dr. Klein has a 12-year teaching history, concentrated in pediatrtic pharmacotherapy; an 8-year history of proving experiential rotations to PharmD candidates; and a number of committee involvements in academia to contribute to growth and development of curricular issues learning throughout the academic process of pharmacy education. She has clearly demonstrated commitment to the ongoing process of educating and mentoring future pediatric pharmacy practitioners.

5-Apr-12 10:00 AM

Highlighting Member Research: Emma Tillman, PharmD

Sandra Benavides - noemail@ppag.org — Thu, 05 Apr 2012 15:00:00 GMT

The PPAG Research Committee is shining the spotlight on member research. In this article, they highlight Emma Tillman, PharmD of the University of Tennessee Health Science Center and her work related to PNALD.

Emma Tillman, PharmD is a Research Assistant Professor in the Department of Clinical Pharmacy at the University of Tennessee Health Science Center and a clinical pharmacist in the area of pediatric nutrition and metabolic support at Le Bonheur Children’s Hospital. She is a graduate of Butler University College of Pharmacy and Health Sciences, where she earned her Doctor of Pharmacy in 2007. Dr. Tillman completed a one year residency and a three year fellowship in pediatric nutrition and metabolic support at the University of Tennessee Health Science Center and Le Bonheur Children’s Hospital in Memphis, TN.

In December 2007 during her residency, she became very interested in parenteral nutrition associated liver disease (PNALD). In the brief six months that she had been at Le Bonheur she had already observed the deaths of two infants from PNALD and was following many other patients that had progressive disease. She had read case studies from Children’s Hospital Boston regarding the use of Omegaven, a fish oil based intravenous fat emulsion for the treatment of PNALD. This product is not FDA approved; therefore, they were unable to obtain it for or use at Le Bonheur.

She approached her faculty preceptors (Dr. Emily Hak and Dr. Richard Helms) about using enteral fish oil for the treatment of PNALD. Enteral fish oil was initiated in six patients with PNALD. Complete reversal of disease was observed in four patients and improvement was observed in the remaining two patients. Recent evidence has suggested that omega-3 polyunsaturated long-chain fatty acids (ω3PUFA) may be effective for the treatment and/or prevention of PNALD, although the mechanism has not been defined.

Dr. Tillman has developed a translational research program including a pilot clinical trial evaluating potential early markers of PNALD and treatment with ω3PUFA, and this clinical study is complimented with cell culture experiments aimed to evaluate cellular pathways that are affected by ω3PUFA in a PNALD model. Results of this research will not only provide a better understanding of PNALD, but also increase understanding of cellular pathways affected by ω3PUFA. This could then potentially be applied to other diseases where ω3PUFA have shown benefit.

5-Apr-12 10:00 AM

Recombinant Factor VIIa in Children

Sandra Benavides - noemail@ppag.org — Thu, 05 Apr 2012 15:00:00 GMT

A survey was developed and sent to the membership of PPAG to describe the use of recombinant factor VIIa in pediatric patients. A total of 106 members responded to the survey and provided data on indications, doses used, formulary status and prescribing restrictions for recombinant factor VIIa. The hospitals represented included children’s hospital within a larger or adult hospital (48%), free standing children’s hospital (35%), and a pediatric ward located within an adult hospital (19%). Respondents were mainly from hospitals with more than 101 pediatric beds (62%). Additionally, 77% of the hospitals surveyed were associated with education and listed themselves as either community teaching hospital (40%) or university affiliated (37%). A clinical pharmacist was represented on interdisciplinary teams within the following areas: PICU (81%), NICU (77%), Hematology/Oncology (69%), and General pediatrics (64%).

Of the institutions that responded to the survey, 91% have recombinant factor VIIa on formulary. For those that do not have it on formulary, 73% will make it available when necessary. One-half of the institutions restrict the use of recombinant factor VIIa to hematology/oncology (85%), critical care (60%), surgery/trauma (48%), cardiology/cardiovascular surgery (31%), emergency medicine (21%), and gastroenterology (6%). Eight three percent of institutions allow the medication to be used in non-hemophiliac children. Table 1 list the various indications and doses for recombinant factor VIIa.

Table 1

Indication	Response	Median dose	Range of doses reported
Hepatic failure	26%	90 mcg/kg	40-140 mcg/kg
GI bleed	21%	90 mcg/kg	45-125 mcg/kg
Pulmonary hemorrhage	14%	90 mcg/kg	90 mcg/kg
Non-IVH intracranial hemorrhage	19%	90 mcg/kg	40-170 mcg/kg
Post-cardiac surgery	38%	90 mcg/kg	35-125 mcg/kg
Traumatic brain injury	22%	90 mcg/kg	80-90 mcg/kg
Bone marrow transplantation	3%	90 mcg/kg	-
DIC	29%	90 mcg/kg	30-140 mcg/kg
Acetaminophen overdose	0%	-	-
Anticoagulant reversal	9%	-	10-125 mcg/kg

5-Apr-12 10:00 AM

Best Practice Awards Announced

Matthew Helms - noemail@ppag.org — Thu, 05 Apr 2012 14:00:00 GMT

The Advocacy Committee is pleased to announce the 2012 recipients of the PPAG Best Practice Awards.

Dr. Jill Johnson and Dr. James McCord for the Children's Hospitals and Clinics on Minnesota in St. Paul, MN are recognized for "Medication Therapy Management (MTM) in a Pediatric Medical Home."

Dr. James Tjon and his colleagues at Sick Kids Hospital in Toronto, Ontario, Canada are recognized for "A Descriptive Pilot for Clinical Pharmacy Services in a Pediatric Clinic for Children with Medical Complexity."

The Best Practice Awards, sponsored by Lexicomp, will be presented at the 21st Annual PPAG Conference in Houston, Texas on April 20, 2012.

5-Apr-12 9:00 AM

MRSA Surveillance in Pediatric Patients

Sandra Benavides - noemail@ppag.org — Thu, 05 Apr 2012 14:00:00 GMT

Methicillin resistant Staphylococcus Aureus (MRSA) has become a common pathogen in the pediatric population. The Pediatric Pharmacy Advocacy Group (PPAG) surveyed its membership to determine current MRSA surveillance practices. A total of 164 members responded to the survey. Of the respondents, 37% reported practicing in a children’s hospital within a hospital system, 35% in a free standing children’s hospital, and 26% in a pediatric ward located within an adult hospital. Most of the respondents (58%) reported more than 101 pediatric beds in their institutions. Additionally, 81% of the hospitals surveyed were associated with education and listed themselves as either community teaching hospital (45%) or university affiliated (37%). A clinical pharmacist was represented on interdisciplinary teams within the following areas: NICU (81%), PICU (80%), General Pediatrics (75%), Hematology/Oncology (61%), and Infectious Disease (48%). A pharmacist was reported to be a member of the institution’s infection control committee in 63% of the institutions.

The results indicated that although not all pediatric patients admitted to the hospital were screened for MRSA colonization (81%), MRSA surveillance was conducted in some pediatric patients (89%). The most common patient screened within 48 hours of admission included children with a history of MRSA infection (47%) or colonization (42%), all neonates (34%), patients transferred from another acute care facility (24%), and patients with a known exposure to MRSA (22%). Also, 50% reported that children admitted to a specific unit (e.g., ICU, Heme/Onc, Transplant) were screened upon admission. Only 40% reported having a screening protocol to identify children at risk for MRSA, which was typically for children with a history of MRSA colonization (76%) or infection (78%). During a hospital or community outbreak of MRSA, only 49% of institutions reported screening children in that time period. In those that do screen children, the majority only screen those in the affected patient unit (68%). In only 20% of the responses were children in all units screened. The most common sites screened included bilateral anterior nares (77%), open lesions or draining wounds (25%), and sputum (15%). With regard to healthcare workers, only 2% of institutions surveyed routinely screen healthcare workers for MRSA colonization and only 30% screen during outbreaks/clusters.

Infection control practices for children found to be MRSA carriers include hand washing with alcohol-based waterless product before entering the room for hospital personnel (71%), isolation room (66%), gloves (66%) and gowns (58%) for anyone entering the patient’s room (66%), or gloves (61%) and gowns (30%) for only those in direct contact with patient. Handwashing with soap and water before and after leaving the room is implemented in 45% of the institutions. Other practices include masks for anyone entering the room (23%) or for those entering a room with a positive respiratory culture only (16%). In those that utilize an isolation room for infection control, isolation can be discontinued when decolonization treatment is given and subsequent cultures are negative (36%), not during the current admission (32%), and in 31% continued upon readmissions.

5-Apr-12 9:00 AM

Gideon Koren, MD Selected as the 2012 Yaffe Award Recipient

Thu, 09 Feb 2012 16:00:00 GMT

Gideon Koren, MD, FRCPC, FACMT, has been selected as the 2012 recipient of the Sumner Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics. Dr Koren is a pediatrician and toxicologist–clinical pharmacologist. He is Professor of Pediatrics, Pharmacology, Pharmacy, and Medical Genetics, and a Senior Scientist at The University of Toronto and the Hospital for Sick Children, and is Professor of Medicine, Pediatrics and Physiology-Pharmacology at the University of Western Ontario. He is the founder and director of the Motherisk Program in Toronto. He graduated from the Sackler School of Medicine at Tel Aviv University in 1974 and completed a pediatric residency in 1980 at Tel Aviv University, followed by 2 years of subspecialty training in pediatric nephrology, focusing on the renal damage caused by medications.

Between 1982 and 1986 he completed his training in clinical pharmacology-toxicology at the University of Toronto and The Hospital for Sick Children. In 1985 he received a diploma in clinical toxicology from the American Board of Medical Toxicology.

In 1985 Dr Koren founded, and has directed ever since, the Motherisk Program, a national counseling and research center for women and health professionals on the safety/risk of drugs, chemicals, radiation, infections during pregnancy, and lactation.

His research programs are supported by the Canadian Institutes for Health Research, the National Institutes of Health, the March of Dimes, Physician Services Inc, Health Canada, the Ontario Ministry of Health, and the pharmaceutical industry.

Dr Koren has published more than 1300 peer-reviewed scientific papers and 13 medical-scientific books, mostly in the field of human toxicology. He is the editor in chief of the international journal Therapeutic Drug Monitoring and Clinical Toxicology, and of the new peer-review journal Fetal Alcohol Research. He holds the Ivey Chair in Molecular Toxicology at the University of Western Ontario. Dr Koren has won numerous scientific awards in Canada and internationally, including the Rawls-Palmer award from the American Society for Clinical Pharmacology and Therapeutics (1977), and the Outstanding Achievement Award from the Canadian Society for Clinical Pharmacology. He has supervised in his laboratory trainees from more than 40 countries worldwide. Dr Koren discovered and described the use of hair analysis to detect long-term exposure to drugs of abuse (e.g., cocaine, heroin, crystal meth) both in adults and neonates, opening up tremendous opportunities to explain poisoning, toxicity, and effects on health and behavior. His group has documented for the first time that infants possess long-term memory for pain inflicted by circumcision at infancy.

Dr. Koren will present, "Drugs in Pregnancy; Treating the Mother- Protecting the Unborn" during the 11th Annual Yaffe Award Presentation and Lecture will be held in Houston, Texas on April 20, 2012 during the 21st PPAG Annual Meeting and Pediatric Pharmacy Conference.

9-Feb-12 10:00 AM

Highlighting Member Publications: Chad A. Knoderer

Tue, 07 Feb 2012 22:30:00 GMT

The PPAG Research Committee highlights recent articles published by PPAG members in various peer-reviewed Journals. In this article the committee discusses Dr. Chad Knoderer’s assessment of antibiotic allergies in children. The complete citation is: Miller LE, Knoderer CA, Cox EG, Kleiman MB. Assessment of the validity of reported antibiotic allergic reactions in pediatric patients. Pharmacotherapy 2011;31:736-41.

Chad A. Knoderer is an Assistant Professor of Pharmacy Practice at Butler University College of Pharmacy and Health Sciences in Indianapolis, Indiana. He has worked extensively with co-author Elaine Cox, MD to establish the Pediatric Antimicrobial Stewardship Program at Riley Hospital for Children in Indianapolis, Indiana. He is a graduate of Butler University College of Pharmacy and Health Sciences, where he earned his Doctor of Pharmacy in 1999. Dr. Knoderer completed two years of residency training at Indiana University Health and Riley Hospital for Children after graduation.

While rounding with the pediatric infectious diseases team, a team-member suggested to Dr. Knoderer that parent reported antibiotic allergies are not completely accurate. This suggestion ultimately was developed into a research question regarding the validity of parent-reported antibiotic allergies. Working with Dr. Lauren Miller, a current PGY2-Pediatric resident, a research project entitled “Assessment of the validity of reported antibiotic allergic reactions in pediatric patients” was conducted. The study set out to determine whether a parent-reported antibiotic allergy was likely to have been immunologically mediated, which is an important question to address in children given increases in bacterial resistance.

This prospective study randomly selected 100 children ages 1 month to 18 years in whom guardians reported an allergy to an antibiotic at the time of admission to the hospital. The guardians were subsequently interviewed using a standard allergy assessment questionnaire developed by the research team. Fifty-eight percent of reported allergies were ultimately categorized as immunologically-mediated reactions, 27% as non-immunologically-mediated adverse drug reactions, 3% as no reaction, and 12% as unknown. Dr. Knoderer and colleagues conclude that there are opportunities to improve the assessment and documentation of reported antibiotic allergies in pediatric patients. Use of an allergy assessment questionnaire may reveal discrepancies that may necessitate further evaluation which may ultimately impact antibiotic utilization.

7-Feb-12 4:30 PM

Clinical Coordinator

Wed, 16 May 2012 05:00:00 GMT

Title: Clinical Coordinator Description: At Nationwide Children's, we recognize that our work is far too important for us not to be the very best at it. And we're nationally recognized for doing so. For the fifth straight year, we've been ranked in the U.S. News & World Report's America's Best Children's Hospitals. Seeing nearly 1 million patients annually, we are one of the country's largest not-for-profit freestanding pediatric health care networks. The department of Pharmacy staff consists of over 100 full-time equivalents (FTE) of clinical and staff pharmacists, nationally certified technicians and support staff working together in a collaborative, integrated, teaching environment. The Clinical Coordinator is responsible for providing clinical pharmacy services to a patient population/service. The incumbent will lead the inpatient and ambulatory clinical pharmacy staffs to provide high quality pharmacy care, provide education to students and residents, and...

Clinical Pharmacy Manager

Fri, 27 Apr 2012 05:00:00 GMT

Title: Clinical Pharmacy Manager Description: As a member of the pharmacy leadership team, this manager is responsible for supervising and developing the activities of the pharmacists and staff assigned to patient care roles and to maintain a clinical practice. The Clinical Pharmacy Manager has varied responsibilities, some of which include: Clinical leadership for the practice area including monitoring staffing needs and assuring appropriate staffing levels are maintained Oversees and/or directs PGY2 pediatric residency program In concert with Pharmacy Operations Manager, provide oversight for scheduling of clinical pharmacists and faculty Responsible for performance evaluations Leads staff development projects (design, implementation, measuring impact) Assists in planning, design, implementation and demonstration of the value of pharmacy services Maintains relationships with nursing and medical staff leadership to achieve departmental, hospital...

PEDIATRIC CLINICAL PHARMACIST

Fri, 20 Apr 2012 05:00:00 GMT

Title: PEDIATRIC CLINICAL PHARMACIST Description: This pediatric clinical pharmacist will provide pharmaceutical services to the pediatric patient population with focus in the 40-bed pediatric nursing unit. This pharmacist will foster relationships with hospitalists, pediatricians, pediatric sub-specialists, and nurses. Responsibilities will include order review and verification in the electronic medical record, provision of pharmacokinetic and nutritional support services, patient rounding, participation on the code team, patient/parent education, and participation in quality improvement activities, among other responsibilities as needed. This pharmacist is an active member of the Pediatric P&T subcommittee and will serve as a preceptor for PGY-1 and PGY-2 residents, as well as students from numerous schools of pharmacy. Required Experience: Pharm.D. with PGY-2 specialty residency in pediatrics, or PGY-1 residency and 2 years pediatric pharmacy practice experience...

Pharmacy Clinical Coordinator Peds

Thu, 19 Apr 2012 05:00:00 GMT

Title: Pharmacy Clinical Coordinator Peds Description: HealthONE - Presbyterian/St. Luke's Medical Center and the Rocky Mountain Hospital for Children, located in the heart of Denver, Colorado, serves as a regional tertiary referral center for a multi-state area. We feature over 80 specialties and 1,000 specialists and primary care physicians. Our staff provides compassionate and innovative care while working alongside top physicians and helping some of the most challenging and rewarding surgical and medical patients. The pharmacy team consists of 65 diverse and talented professionals dedicated to providing exceptional pharmaceutical care. They provide a broad range of clinical services and oversee the medication management system including some of the most advanced drug distribution technologies available. Clinical services include pharmacokinetics, anticoagulation, specialized nutrition support, antimicrobial stewardship, medication reconciliation, and patient education....

Pharmacy Technicians, Start Date: August 2012, Various Shifts

Fri, 23 Mar 2012 05:00:00 GMT

Title: Pharmacy Technicians, Start Date: August 2012, Various Shifts Description: Nemours is seeking Pharmacy Technicians (START DATE: AUGUST 2012) to join our team at the Nemours Children's Hospital in Orlando, Florida. As one of the nation's leading pediatric health care systems, Nemours provides world-class clinical care in four states: Delaware, Florida, New Jersey and Pennsylvania. In 2012, Orlando will be home to Nemours Children's Hospital, part of a unique, state-of-the-art health campus, which will include a new Nemours Children's Clinic, an ambulatory diagnostic center and extensive research and education facilities. As part of Nemours' fully integrated system of care, we have access to the specialists and resources of the Nemours/Alfred I. duPont Hospital for Children in Wilmington, Delaware - named among the nation's best in pediatric specialty care by U.S. News & World Report. Description: This Pharmacy Technician position is...

Clinical Pharmacist, Start Date: August 2012, Days

Fri, 23 Mar 2012 05:00:00 GMT

Title: Clinical Pharmacist, Start Date: August 2012, Days Description: Nemours is seeking a Clinical Pharmacist (START DATE: 08/2012) to join our team at the Nemours Children's Hospital in Orlando, Florida. This position is responsible for providing Pharmacy Services within the Pharmacy Department at Nemours Children's Hospital. The Clinical Pharmacist will review, clarify, verify and provide recommendations for medication orders and be responsible for the dispensing of medications and the activities surrounding dispensing throughout the hospital and its associated clinics at Medical City. Job Duties • Reviews, interprets and verifies medication orders for accuracy using sound principles, accounting for pharmacology of the drug, pharmacodynamic and pharmacokinetic variations in drug absorption, distribution, metabolism and elimination with responsibility for establishing and overseeing the delivery and preparation of unit dose and parenteral pharmaceuticals....

Clinical Pharmacist, Start Date: August 2012, Nights

Fri, 23 Mar 2012 05:00:00 GMT

Title: Clinical Pharmacist, Start Date: August 2012, Nights Description: Nemours is seeking a Clinical Pharmacist - 3rd Shift (START DATE: 08/2012) to join our team at the Nemours Children's Hospital in Orlando, Florida. This position is responsible for providing Pharmacy Services within the Pharmacy Department at Nemours Children's Hospital. The Clinical Pharmacist will review, clarify, verify and provide recommendations for medication orders and be responsible for the dispensing of medications, and the activities surrounding dispensing throughout the hospital and its associated clinics at Medical City. Job Duties • Reviews, interprets and verifies medication orders for accuracy using sound principles, accounting for pharmacology of the drug, pharmacodynamic and pharmacokinetic variations in drug absorption, distribution, metabolism and elimination with responsibility for establishing and overseeing the delivery and preparation of unit dose and parenteral...

Pediatric clinical pharmacist

Mon, 20 Feb 2012 06:00:00 GMT

Title: Pediatric clinical pharmacist Description: King Abdulaziz Medical City (KAMC) in Jeddah is a 420-bed tertiary care facility that is located in the western region of Saudi Arabia. The facility includes new state-of-the-art developments such as cardiac and oncology center, 26 beds Intensive Care Unit (ICU), ambulatory care, and emergency care. Other adult and pediatric services include surgical, medical, obstetrics/gynecology, general pediatric, pediatric oncology, pediatric ICU, Neonatal ICU, and home health care service. Withen the next few years we will have a new state of the art 350beds pediatric center. In addition, KAMC is affiliated with King Saud bin Abdul Aziz University for Health Sciences. BENEFITS AND COMPENSATIONS 1. $88,000-102000+/yr Tax Free Salary (every thing in KSA is tax free) based in experience 2. Able to Save the Majority of Your Salary 3. Yearly Service Award (Re-contracting Bonus). Our Contracts are for one year, with a sign on bonus...

History of the Pediatric Pharmacy Advocacy Group

Mon, 07 May 2012 03:58:10 GMT

This year the Pediatric Pharmacy Advocacy Group marks its 30 year anniversary. Like nearly all worthy causes, the idea for the Pediatric Pharmacy Advocacy Group (PPAG) started with a conversation among a small group of friends and colleagues. The Early Years In 1979 Dr. Doug Smith, Dr. Robert Poole, and Mr. Steve Allen began discussing the need for an organization aimed at helping pediatric pharmacy directors to better serve their unique patient populations. These trailblazers met informally and then formally at the American Society of Health-Systems Pharmacist's Midyear Clinical Meeting. Over the next six years, the group expanded and included Pharmacy Directors from across the United States. At these meetings a core group of leaders emerged. Mr. Doug Smith (Chicago, IL) served as President and Chairman of the Board from 1985-1995. Other members of this charter group include: Mr. Stephen Allen (Washington, DC), Mr. Joe Sceppa (Boston, MA), Mr. Henry Wedemeyer...

Sumner J. Yaffe Lifetime Achievement Award

Fri, 27 Apr 2012 14:42:14 GMT

The Sumner J. Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics will be given annually in recognition of signficant and sustained contributions toward the improvement of children's health through the expansion of the field of pediatric pharmacology and therapeutics. The Yaffe Award was established by the PPAG Board of Directors in 2002. Dr. Yaffe is a founding father of developmental and pediatric pharmacology and has influenced the field throughout his entire career. ABOUT SUMNER J. YAFFE May 9, 1923 - August 10, 2011 Please read In Memoriam: Sumner J. Yaffe, The Father of Pediatric Pharmacology written by Georgia Giaicoia, MD and Michael Reed, PharmD. (J Pediatric Pharmacol Ther 2011;16(3):162-166. By Stephen P. Spielberg, MD, PhD (written in 2003) Dr. Sumner J. Yaffe was born in Boston, graduated from Boston Latin School, and Harvard College (with an interruption during World War II to serve in the Armed Forces). He received...

21st Annual PPAG Meeting CONFERENCE RESOURCE GUIDE

Mon, 23 Apr 2012 19:24:49 GMT

Welcome to the 21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference. This page will serve as your one-stop shop for everything related to the Conference. Click here for the text-only version of this page. THIS IS WHAT YOU ARE LOOKING FOR: CE Information In order to receive continuing education credit, you must fill out a Post-Conference Evaluation form online. To view the form, go to: http://www.surveymonkey.com/s/21_ConferenceEval You must complete the form on or before April 27, 2012. Certificates will be distributed after April 27. It is recommended that you wait until the completion of ALL session before you fill out the form. General Information. Tips and ideas on how to have a great conference experience. Crafted for you! Information about travel, the Houston Marriott, and attractions within one-mile of the Hotel (Conference Map is included). Quick Guide Schedule- Printable (PDF) Schedule including room assignments: Entire...

21st Annual PPAG Meeting HANDOUTS

Sat, 21 Apr 2012 23:37:16 GMT

Handouts available as of April 9, 2012 are posted within the schedule below. Missing handouts will be available prior to the Conference. For speaker/faculty bios, learning objectives, and program numbers go to: http://www.ppag.org/21_objectives. Infectious Diseases The ID Block features two educational tracks: (1) Review and (2) Advanced. Level 1 programs provide a review of current practices in the topic identified and are appropriate for both new practitioners and those seeking to update their knowledge base. Level 2 programs provide an advances review of the identified optic and new developments in the field. Level 2 programs are appropriate for the advanced level practitioner. Infectious Disease Key Review Advanced WEDNESDAY, April 18, 2012 Infectious Diseases Block 8am - 4pm ...

homepage - conference info

Thu, 19 Apr 2012 11:08:11 GMT

21st PPAG Annual Meeting and
Pediatric Pharmacy Conference

Houston Marriott at the Texas Medical Center

Houston, Texas

April 18-22, 2012

CONFERENCE RESOURCE GUIDE (for participants)

Student Group Recognition Program

Wed, 18 Apr 2012 20:24:18 GMT

The Pediatric Pharmacy Advocacy Group recognizes student groups and organizations on college campuses throughout the US. Student organizations help you make strong peer-to-peer connections that can make a real difference in your career and practice.

Through networking events, local programming, regional news and volunteer opportunities, Student Groups allow you to build a community of peers, advance your career and volunteer within the pediatric pharmacy community. These activities are recognized at a national level through PPAG.

Search recognized Student Groups here

If you are interested in seeking recognition for your student group, please view the following information:

1. Guidelines (Click here for guidelines, suggestions, and information)

2. Application (Fill out and submit this application for consideration)

Local Communities and Networks Recognition Program

Wed, 18 Apr 2012 20:15:18 GMT

The Local Communities and Networks of the Pediatric Pharmacy Advocacy Group help you make strong peer-to-peer connections that can make a real difference in your career and practice.

Through networking events, local programming, regional news and volunteer opportunities, the Local Networks allow you to build a community of peers, advance your career and volunteer within the pediatric pharmacy community. These activities are recognized at a national level through PPAG.

Join a Local Network today.

Search Local Communities

If you are interested in starting a Local Community in your area, please view the following information:

Local Community and Network Guidelines

Local Community and Network Application

21st Annual PPAG Meeting LEARNING OBJECTIVES

Fri, 13 Apr 2012 19:50:37 GMT

The Conference features two educational blocks. Infectious Diseases will be the focus of the Conference April 18-20, 2012. The Conference also offers a look at Clinical Leadership and Management in Pediatric Pharmacy from April 20-22, 2012 To return to the AGENDA-AT-A-GLANCE, click here To return to Conference Information and Registration page, click here Wednesday, April 18, 2012 Infectious Diseases 8 am-4 pm Registration 8 am-9 am Continental Breakfast 9-10 am Community Acquired Pneumonia- Evidence for Changes in Practice 0180-0000-12-101-L01-P (0.1 Application-based CEU) William Maish, PharmD Clinical Pharmacist Specialist, Pediatric Internal Medicine Arnold Palmer Hospital for Children ...

Practice Statements and Guidelines

Wed, 11 Apr 2012 23:40:27 GMT

The need for authoritative guidance in pediatric pharmacy practice has grown with changes in health care and with shifting influences from regulatory, accrediting, risk-management, financing, and other bodies. The PPAG Advocacy Committee develops official professional position statements for this purpose. PPAG offers therapeutic position statements that respond to specific therapeutic issues. These statements are thorough, evidence-based recommendations of drug use. PPAG also offers position statements on public policy issues that are directed to health care professionals, public officials, and the general public. PPAG position statements provide guidance and direction to PPAG members, pharmacy practitioners, and other audiences who affect pharmacy practice. Their use by members and other practitioners is strictly voluntary, and their content should be assessed and adapted to meet the needs of specific practice settings. Below is a list of our guidelines and position...

Pediatric Pharmacists' Participation in Cardiopulmonary Resuscitation Events

Wed, 11 Apr 2012 23:37:41 GMT

PPAG understands the dilemma and varying factors that many institutions face concerning the routine participation of pharmacists in emergency resuscitation activities. Acknowledging these obstacles, PPAG encourages all institutions to strongly consider creating, adopting and upholding policies to address pharmacists' participation in code events because of the profound and evidenced impact pharmacist participation has shown on hospital medication error and mortality rates in children. PPAG advocates that all institutions requiring a pharmacist's participation in codes should consider adoption of preparatory training programs. While PPAG does not advocate any one specific program, consideration should be taken to ensure that pharmacists are educated on the pharmacotherapy of drugs used in the CPR process including but not limited to, inotropes and vasoactive medications, BLS, medication compatibility, ACLS/PALS algorithms, and a general familiarity with the institutional code cart...

Pediatric Pain Management Webinar

noemail@ppag.org — Mon, 23 Jan 2012 20:00:00 GMT

Objectives:

To evaluate the effectiveness of the educational session, speaker, educational format, and educational delivery.

Release Date: 23-Jan-12 2:00 PM
Expiration Date: 8-Feb-12 11:00 PM

Please fill out the form by February 8, 2012 (midnight eastern time)

MRSA: What do you do when you can't use Vancomycin?

noemail@ppag.org — Tue, 27 Sep 2011 16:00:00 GMT

Objectives:

To evaluate the effectiveness of the educational session, speaker, educational format, and educational delivery.

Release Date: 27-Sep-11 11:00 AM
Expiration Date: 6-Oct-11 3:00 AM

Please fill out the form by October 5, 2011.

Evaluation of Pediatric Aged-Based Competency: Anatomic and Physicologic Differences Between Childre

noemail@ppag.org — Thu, 21 Apr 2011 18:45:00 GMT

Objectives:

The goal of this survey is to evaluate the qualify and effectiveness of online course content.

Release Date: 21-Apr-11 1:45 PM
Expiration Date: 20-Jul-11 1:45 PM

You will be asked to read a series of statements. Please indicate if you strongly agree, somewhat agree, strongly disagree, somewhat disagree, or are neutral.

Acthar Gel (repository corticotrophin injection) Survey

noemail@ppag.org — Mon, 26 Feb 2007 17:00:00 GMT

Objectives:

This is a survey for pharmacies that order Acthar Gel (repository corticotrophin injection). The product is currently indicated for the treatment of acute exacerbations of multiple sclerosis and other conditions, and it is used off-label for treatment of infantile spasms. The maker of Acthar Gel, Questcor, filed a supplemental new drug application for the infantile spasms indication in August 2006. The company is now trying to understand how much of Acthar Gel usage is for multiple sclerosis and how much is for infantile spasms.

PPAG has received a small grant to conduct this survey.

Release Date: 26-Feb-07 11:00 AM
Expiration Date: 10-Apr-07 4:00 PM

if you use Acthar Gel, please fill out the survey to the best of your ability. Please coordinate within your institution so we do not receive duplicate information. We are not asking for facility name or participant information (involuntarily) in order to ensure confidentiality.

Medication Administration in Schools

noemail@ppag.org — Wed, 12 Jul 2006 19:00:00 GMT

Objectives:

We are looking to identify challenges and or cases within local school system or daycare settings.

For example: "Johnny’s" school doesn’t have a nurse, the school refuses to allow any medication administration, and so a parent goes to school everyday to administer!

The results of this survey will be presented at the 15th Annual Meeting during the Advocacy Workshop.

Release Date: 12-Jul-06 2:00 PM
Expiration Date: 10-Sep-06 2:00 PM
Please read and respond to the following questions.

What are your thoughts about PediNet?

noemail@ppag.org — Tue, 08 Nov 2005 15:00:00 GMT

Objectives: The Membership Services Committee values your opinion about the services PPAG provides its members. This survey was created to get your feedback about our PediNet Member Forums.

Release Date: 8-Nov-05 9:00 AM
Expiration Date: 14-Apr-06 9:00 AM
Please answer the questions provided. There are only 8 questions to answer. It should not take that long to complete.

2006-07 Educational Needs Assessment

noemail@ppag.org — Thu, 06 Oct 2005 02:00:00 GMT

Objectives: To better understand the continuing educational needs of our members.

Release Date: 5-Oct-05 9:00 PM
Expiration Date: 3-Jan-06 9:00 PM

Please offer comments in the text boxes provided.

Antifungal Survey for Stem Cell Transplantation/ Hematology-Oncology

noemail@ppag.org — Thu, 30 Jun 2005 21:00:00 GMT

Objectives:

To evaluate the use of antifungal agents in the pediatric hematology-oncology (H/O) and 

stem cell transplant (SCT) population and to assess differences in practice among various 

institutions.

Release Date: 30-Jun-05 4:00 PM
Expiration Date: 30-Mar-06 4:00 PM
Please participate in the following survey. Any PPAG member or affiliate can take the survey. Please coordinate your response within your institution to avoid duplicity.

To climb steep hills, requires slow pace at first.

Tue, 21 Jun 2005 23:24:19 GMT

"To climb steep hills, requires slow pace at first."

William Shakespeare, Henry VIII

Approach to the Pediatric Prescription in a Community Pharmacy

2012-04-30T13:00:00Z

Instructor: Sandra Benavides, PharmD; Donna Huynh, PharmD, BCPS; Jill Morgan, PharmD; Leslie Briars PharmD

Link to article [to be posted]

Core Competency Series: Pediatric Parenteral Nutrition

2010-03-19T13:00:00Z

Instructor: Kathleen Gura, PharmD

This program is a one hour Power Point presentation with synched audio. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the course handout (PDF), click here. After completion of the program, you may take the post-test to receive credit.

Extreme Dosing: Case Studies in Pediatric Transplantation

2010-03-19T13:00:00Z

Instructor: William McGhee

Extreme Dosing in Overweight/Obese Children - Focus on DVT Prophylaxis

2010-03-19T13:00:00Z

Instructor: Peter Johnson

Extreme Dosing in CF: Aminoglycosides

2010-03-19T13:00:00Z

Instructor: Heidi Smith Hoopingarner

Hot Topics in Pediatric ID, Critical Care, and Nutrition

2009-09-27T13:00:00Z

Instructor: Jeff Cies, PharmD and Betsy Walter, PharmD

This program is a two hour Audio presentation synced with PowerPoint slides. The program contains three sections. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF documents for each section, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Medication Use During ECMO and Continuous Renal Replacement Therapy

2009-09-26T13:00:00Z

Instructor: Brenda Dodson

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Community-Acquired MRSA in Pediatric Patients

2009-09-26T13:00:00Z

Instructor: Kristin Klein, PharmD

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Management of Pediatric Chemical Casualties: Are We Prepared

2009-09-25T13:00:00Z

Instructor: Elora Hilmas

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Adolescents, Sexuality, and The Pediatric Pharmacist

2009-09-25T13:00:00Z

Instructor: Veenod Chulani

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

PPAG RSS Feed

22nd Annual PPAG Meeting and 2013 Pediatric Pharmacy Conference on 1-May-13 8:30 AM

Conference Agenda Information

Call For Abstracts

Registration Information and Policy

Hotel Information-- Affordable Rates!

About Indianapolis, IN

Highlighting Member Publication: Spencer Durham

FDA alert regarding accidental exposure to fentaNYL patches

Decision '12: Board Election Results

President-Elect William (Bill) Maish, PharmD

Treasurer Jeffrey Low, PharmD

Secretary Kay Kyllonen, PharmD, FPPAG

Director-At-Large (2012-2015) Tracy Hagemann, PharmD, FCCP, FPPAG

Director-At-Large (2012-2015) David Hoff, PharmD, FCCP

Director-At-Large (2012-2013) Lisa Lubsch, PharmD

Fellows in the Pediatric Pharmacy Advocacy Group (FPPAG) Inductees Announced

Tracy M. Hagemann, PharmD, FCCP, FPPAG

Kristin Klein, PharmD, FPPAG

Highlighting Member Research: Emma Tillman, PharmD

Recombinant Factor VIIa in Children

Best Practice Awards Announced

MRSA Surveillance in Pediatric Patients

Gideon Koren, MD Selected as the 2012 Yaffe Award Recipient

Highlighting Member Publications: Chad A. Knoderer

Clinical Coordinator

Clinical Pharmacy Manager

PEDIATRIC CLINICAL PHARMACIST

Pharmacy Clinical Coordinator Peds

Pharmacy Technicians, Start Date: August 2012, Various Shifts

Clinical Pharmacist, Start Date: August 2012, Days

Clinical Pharmacist, Start Date: August 2012, Nights

Pediatric clinical pharmacist

History of the Pediatric Pharmacy Advocacy Group

Sumner J. Yaffe Lifetime Achievement Award

21st Annual PPAG Meeting CONFERENCE RESOURCE GUIDE

21st Annual PPAG Meeting HANDOUTS

homepage - conference info

Student Group Recognition Program

Local Communities and Networks Recognition Program

21st Annual PPAG Meeting LEARNING OBJECTIVES

Practice Statements and Guidelines

Pediatric Pharmacists' Participation in Cardiopulmonary Resuscitation Events

Pediatric Pain Management Webinar

MRSA: What do you do when you can't use Vancomycin?

Evaluation of Pediatric Aged-Based Competency: Anatomic and Physicologic Differences Between Childre

Acthar Gel (repository corticotrophin injection) Survey

Medication Administration in Schools

What are your thoughts about PediNet?

2006-07 Educational Needs Assessment

Antifungal Survey for Stem Cell Transplantation/ Hematology-Oncology

To climb steep hills, requires slow pace at first.

Approach to the Pediatric Prescription in a Community Pharmacy

Core Competency Series: Pediatric Parenteral Nutrition

Extreme Dosing: Case Studies in Pediatric Transplantation

Extreme Dosing in Overweight/Obese Children - Focus on DVT Prophylaxis

Extreme Dosing in CF: Aminoglycosides

Hot Topics in Pediatric ID, Critical Care, and Nutrition

Medication Use During ECMO and Continuous Renal Replacement Therapy

Community-Acquired MRSA in Pediatric Patients

Management of Pediatric Chemical Casualties: Are We Prepared

Adolescents, Sexuality, and The Pediatric Pharmacist

Hotel Information--
Affordable Rates!

President-Elect
William (Bill) Maish, PharmD

Treasurer
Jeffrey Low, PharmD

Secretary
Kay Kyllonen, PharmD, FPPAG

Director-At-Large (2012-2015)
Tracy Hagemann, PharmD, FCCP, FPPAG

Director-At-Large (2012-2015)
David Hoff, PharmD, FCCP

Director-At-Large (2012-2013)
Lisa Lubsch, PharmD